ERC Starting Grant · 2017
REsponsive theranostic nanosystems for Advanced Cancer Treatment
REACT aims to dramatically impact the targeted release of diagnostic agents and drugs with nanomedicines that respond to biological cues or changing pathophysiological conditions, thus enabling ultrasensitive diagnosis and exquisite therapy selectivity. Nanomedicine research against cancer focuses on the local targeted delivery of chemotherapeutics to enhance drug efficacy and reduce side effects. Despite all the efforts in the design of chemotherapeutic agents as nanomedicines, hardly any improvement has been translated into benefits for patients’ survival. There is an urgent need for improved carrier systems able to deliver high doses of diagnostic agents and anti-cancer drugs to the…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.